Search Results for "1"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for 1. Results 41 to 50 of 2613 total matches.

Vaccination Recommendations for Bivalent mRNA COVID-19 Vaccines (online only)

   
The Medical Letter on Drugs and Therapeutics • May 01, 2023  (Issue 1675)
Not Previously Vaccinated Previously Vaccinated with Monovalent Vaccine2 Previously Received ?1 Bivalent Dose3 ...
View the Vaccination Recommendations for Bivalent mRNA COVID-19 Vaccines
Med Lett Drugs Ther. 2023 May 1;65(1675):e1   doi:10.58347/tml.2023.1675f |  Show IntroductionHide Introduction

Insulin Degludec (Tresiba) - A New Long-Acting Insulin for Diabetes

   
The Medical Letter on Drugs and Therapeutics • Dec 07, 2015  (Issue 1483)
) for treatment of adults with type 1 or type 2 diabetes. Insulin degludec is the third longacting human insulin ...
The FDA has approved insulin degludec (Tresiba – Novo Nordisk) for treatment of adults with type 1 or type 2 diabetes. Insulin degludec is the third long-acting human insulin analog to be approved by the FDA; insulin detemir (Levemir) and insulin glargine (Lantus, Toujeo) were approved earlier.
Med Lett Drugs Ther. 2015 Dec 7;57(1483):163-4 |  Show IntroductionHide Introduction

Ceftolozane/Tazobactam (Zerbaxa) - A New Intravenous Antibiotic

   
The Medical Letter on Drugs and Therapeutics • Mar 02, 2015  (Issue 1463)
-chain that increases its activity against Pseudomonas aeruginosa.1 Tazobactam inhibits most class ...
The FDA has approved ceftolozane/tazobactam (Zerbaxa – Cubist), a combination of a new cephalosporin antibiotic and a beta-lactamase inhibitor, for intravenous treatment of complicated urinary tract and intra-abdominal infections in adults.
Med Lett Drugs Ther. 2015 Mar 2;57(1463):31-3 |  Show IntroductionHide Introduction

Vuity - Pilocarpine Ophthalmic Solution for Presbyopia

   
The Medical Letter on Drugs and Therapeutics • Feb 07, 2022  (Issue 1643)
Vuity - Pilocarpine Ophthalmic Solution for Presbyopia The FDA has approved Vuity (Abbvie), a 1 ...
The FDA has approved Vuity (Abbvie), a 1.25% ophthalmic solution of the muscarinic receptor agonist pilocarpine hydrochloride, for treatment of presbyopia in adults. Pilocarpine 1%, 2%, and 4% ophthalmic solutions (Isopto Carpine, and others) have been available for years for treatment of glaucoma, but local and systemic adverse effects have limited their use.
Med Lett Drugs Ther. 2022 Feb 7;64(1643):17-8 |  Show IntroductionHide Introduction

COVID-19 Update: FDA Expands Bivalent Vaccine Use, Revises Vaccination Schedules

   
The Medical Letter on Drugs and Therapeutics • May 01, 2023  (Issue 5063)
authorized for use in the US.1 All persons ≥6 months old who completed a primary series with the Pfizer ...
The FDA has amended its Emergency Use Authorizations (EUAs) for the bivalent mRNA COVID-19 vaccines (original and Omicron BA.4/5 strains) manufactured by Pfizer/BioNTech (Comirnaty) and Moderna (Spikevax) to permit their use for all doses administered to persons ≥6 months old. The monovalent Pfizer and Moderna vaccines are no longer authorized for use in the US
Med Lett Drugs Ther. 2023 May 1;65(5063):1   doi:10.58347/tml.2023.5063a |  Show IntroductionHide Introduction

Mirabegron (Myrbetriq) for Overactive Bladder

   
The Medical Letter on Drugs and Therapeutics • Feb 18, 2013  (Issue 1410)
to be approved for any indication in the US. Mirabegron has been marketed in Japan since 2011. Table 1. Some ...
Mirabegron (mir a beg’ ron; Myrbetriq [meer BEH trick] – Astellas), a beta-3 adrenergic agonist, has been approved by the FDA for the treatment of overactive bladder. It is the first beta-3 adrenergic agonist to be approved for any indication in the US. Mirabegron has been marketed in Japan since 2011. OnabotulinumtoxinA (Botox) was also recently approved by the FDA for treatment of overactive bladder and will be reviewed in a future issue.
Med Lett Drugs Ther. 2013 Feb 18;55(1410):13-5 |  Show IntroductionHide Introduction

Clascoterone Cream (Winlevi) for Acne

   
The Medical Letter on Drugs and Therapeutics • Dec 27, 2021  (Issue 1640)
not respond to topical combination therapy, addition of an oral tetracycline is recommended.1,2 The most ...
The FDA has approved Winlevi (Sun), a 1% cream formulation of the androgen receptor inhibitor clascoterone, for treatment of acne vulgaris in patients ≥12 years old. It is the first topical androgen receptor inhibitor to be approved by the FDA.
Med Lett Drugs Ther. 2021 Dec 27;63(1640):202-4 |  Show IntroductionHide Introduction

Sofosbuvir/Velpatasvir (Epclusa) for Hepatitis C

   
The Medical Letter on Drugs and Therapeutics • Aug 15, 2016  (Issue 1501)
— The prevalence of HCV genotypes in the US is about 75% for genotype 1, 20-25% for genotypes 2 and 3, and ...
The FDA has approved Epclusa (Gilead), a fixed-dose combination of sofosbuvir (Sovaldi) and velpatasvir, a new direct-acting antiviral agent, for oral treatment of chronic hepatitis C virus (HCV) infection. Epclusa is the first oral combination to be approved for treatment of all six major HCV genotypes.
Med Lett Drugs Ther. 2016 Aug 15;58(1501):107-8 |  Show IntroductionHide Introduction

Tirzepatide (Mounjaro) for Type 2 Diabetes

   
The Medical Letter on Drugs and Therapeutics • Jul 11, 2022  (Issue 1654)
-like peptide-1 (GLP-1) receptors, to improve glycemic control in adults with type 2 diabetes ...
The FDA has approved tirzepatide (Mounjaro – Lilly), a peptide hormone with activity at both glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors, to improve glycemic control in adults with type 2 diabetes. Tirzepatide, which is injected subcutaneously once weekly, is the first dual GIP/GLP-1 receptor agonist to become available in the US. Selective GIP receptor agonists are not available in the US; GLP-1 receptor agonists have been available for years.
Med Lett Drugs Ther. 2022 Jul 11;64(1654):105-7 |  Show IntroductionHide Introduction

Two New Drugs for HIV Infection

   
The Medical Letter on Drugs and Therapeutics • Jan 14, 2008  (Issue 1277)
class of oral HIV drugs called HIV-1 integrase strand transfer inhibitors (InSTI), has received ...
Raltegravir (Isentress - Merck), the first in a new class of oral HIV drugs called HIV-1 integrase strand transfer inhibitors (InSTI), has received accelerated FDA approval for use in combination therapy for treatment-experienced adults infected with HIV-1 strains resistant to multiple antiretroviral agents.

Maraviroc (Selzentry - Pfizer), the first CCR5 (CC chemokine receptor 5) antagonist has received the same FDA approval but is restricted to use in adults with CCR5-tropic HIV-1 ("R5 virus"). A commercial assay is available for R5 tropism.
Med Lett Drugs Ther. 2008 Jan 14;50(1277):2-4 |  Show IntroductionHide Introduction